EMERYVILLE, Calif., Feb. 12, 2018 /PRNewswire/ -- Santen Inc. today announced that the topline results from the Phase I/II study of DE-122 (carotuximab) for refractory wet age-related macular degeneration (AMD)
Growth Capitalist (https://growthcapitalist.com/2018/02/santen-presents-phase-iii-data-on-de-122-carotuximab-in-patients-with-refractory-wet-age-related-macular-degeneration/?utm_source=rss&utm_medium=rss&utm_campaign=santen-presents-phase-iii-data-on-de-122-carotuximab-in-patients-with-refractory-wet-age-related-macular-degeneration)
EMERYVILLE, Calif., Feb. 12, 2018 /PRNewswire/ -- Santen Inc. today announced that the topline results from the Phase I/II study of DE-122 (carotuximab) for refractory wet age-related macular degeneration (AMD)